Listar por autor "Planas, J.M.M."
Mostrando ítems 1-2 de 2
-
Effectiveness and safety of sofosbuvir‐based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis: results of a multicenter real‐life cohort
Alonso, S.; Riveiro-Barciela, M.; Fernández, I.; Rincón, D.; Real, Y.; Llerena, S.; Gea, F.; Olveira, A.; Fernández-Carrillo, C.; Polo, B.; Carrión, J.A.; Gómez, A.; Devesa, M.J.; Baliellas, C.; Castro-Iglesias, Ángeles; Ampuero, J.; Granados, R.; Pascasio, J.M.; Rubín, A.; Salmerón, J.; Badia, E.; Planas, J.M.M.; Lens, S.; Turnes, J.; Montero, J.L.; Buti, M.; Esteban, R.; Fernández-Rodríguez, C.M. (Wiley, 2016-11-09)[Abstract] Patients with HCV genotype 3 (GT3) infection and cirrhosis are currently the most difficult to cure. We report our experience with sofosbuvir+daclatasvir (SOF+DCV) or sofosbuvir/ledipasvir (SOF/LDV), with or ... -
High efficacy and tolerability of hepatitis C genotype 2 treatment with direct-acting antivirals in real world: analysis of the Hepa-C Registry
Aranda, E.B.; Mariño, Zoe; Calvo, S.; Carrión, J.A.; Fernández, I.; García-Samaniego, J.; Baliellas, C.; Pascasio, J.M.; Albillos, A.; Carrillo, C.F.; Castro-Iglesias, Ángeles; Planas, J.M.M.; Giner, C.P.; Palomares, J.J.M.; Llaneras, J.; Arenas, J.; Fernández-Bermejo, M.; Fernández, C.; López, R.M.G.; García, P.B.; Romero-Gómez, Manuel; Sáez-Royuela, F. (Elsevier, 2017)